![]() ![]() Concomitant use with ombitasvir/paritaprevir/ritonavir, dasabuvir, glecaprevir/pibrentasvir, and sofosbuvir/velpatasvir/voxilaprevir. Major surgery with prolonged immobilisation. Women >35 years who smoke obese (BMI ≥30 kg/m 2). breast or endometrial cancer), undiagnosed vaginal bleeding SLE with positive or unknown antiphospholipid antibodies. ![]() active viral hepatitis, severe cirrhosis), benign or malignant liver tumours known or suspected sex-steroid dependent malignancies (e.g. aura) current or history of pancreatitis associated with severe hypertriglyceridemia, severe hepatic disease (e.g. severe dyslipoproteinaemia, diabetes mellitus with vascular symptoms) cerebrovascular disease, coronary artery disease, thrombogenic valvular or rhythm disorders, severe or uncontrolled hypertension history of migraine with focal neurological symptoms (e.g. hyperhomocysteinaemia, antiphospholipid-antibodies), high risk of arterial thromboembolism due to multiple risk factors or the presence of 1 serious risk factor (e.g. angina pectoris), hereditary or acquired predisposition for arterial thromboembolism (e.g. factor V Leiden mutation, activated protein C resistance, antithrombin-III-deficiency, protein C and S deficiency), current or history of arterial thromboembolism (e.g. DVT, pulmonary embolism), hereditary or acquired predisposition for venous thromboembolism (e.g. Current or history of venous thromboembolism (e.g. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |